PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: S&P CapIQ Cuts Next To Buy From Strong Buy

Tue, 05th Jan 2016 09:43

LONDON (Alliance News) - The following shares received analyst recommendations Tuesday morning:
----------
FTSE 100
----------
S&P CAPITAL IQ CUTS NEXT TO 'BUY' ('STRONG BUY') - TARGET 85 (91) PENCE
----------
CREDIT SUISSE RAISES BUNZL PRICE TARGET TO 1780 (1660) PENCE - 'NEUTRAL'
----------
CREDIT SUISSE RAISES TRAVIS PERKINS TO 'OUTPERFORM' ('NEUTRAL') - TARGET 2255 (1838) PENCE
----------
Deutsche Bank Upgrades Tesco To Buy From Hold Ups Price Target To 210p From 200p
----------
JPMORGAN RAISES HIKMA PRICE TARGET TO 2700 (2500) PENCE - OVERWEIGHT
----------
JPMORGAN RAISES GLAXOSMITHKLINE PRICE TARGET TO 1390 (1370) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES ASTRAZENECA PRICE TARGET TO 4500 (4400) PENCE - 'NEUTRAL'
----------
Cantor Fitzgerald Raises Royal Mail To Buy From Hold Ups Price Target To 530p From 500p
----------
BARCLAYS CUTS ABERDEEN AM TO UNDERWEIGHT (EQUAL WEIGHT) - TARGET 250 (350) PENCE
----------
SOCGEN CUTS MARKS & SPENCER PRICE TARGET TO 595 (652) PENCE - 'BUY'
----------
JPMORGAN RAISES SMITH & NEPHEW PRICE TARGET TO 1089 (1024) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
MORGAN STANLEY CUTS SSP GROUP TO 'UNDERWEIGHT' ('EQUAL-WEIGHT')
----------
HSBC INITIATES JLT GROUP WITH 'BUY' - TARGET 1020 PENCE
----------
JPMORGAN CUTS ROTORK PRICE TARGET TO 170 (180) PENCE - 'NEUTRAL'
----------
JPMORGAN CUTS HALFORDS GROUP PRICE TARGET TO 380 (460) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES BODYCOTE PRICE TARGET TO 510 (500) PENCE - 'UNDERWEIGHT'
----------
JPMORGAN CUTS BTG TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 780 (900) PENCE
----------
GOLDMAN CUTS MELROSE INDUSTRIES PRICE TARGET TO 360 (380) PENCE - 'BUY'
----------
BARCLAYS RAISES LANCASHIRE HOLDINGS PRICE TARGET TO 428 (419) PENCE - UNDERWEIGHT
----------
BARCLAYS RAISES HISCOX PRICE TARGET TO 684 (645) PENCE - 'UNDERWEIGHT'
----------
GOLDMAN CUTS WEIR GROUP PRICE TARGET TO 1500 (1550) PENCE - 'BUY'
----------
GOLDMAN CUTS SPECTRIS PRICE TARGET TO 2130 (2200) PENCE - 'BUY'
----------
Deutsche Upgrades Morrisons To Hold From Sell, Price Target 155p
----------
MAIN MARKET AND AIM
----------
JPMORGAN CUTS OXFORD INSTRUMENTS PRICE TARGET TO 870 (950) PENCE - 'OVERWEIGHT'
----------
GOLDMAN CUTS OXFORD INSTRUMENTS PRICE TARGET TO 685 (700) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES SPIRE HEALTHCARE PRICE TARGET TO 395 (310) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES CAMBIAN PRICE TARGET TO 278 (222) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES ABCAM PRICE TARGET TO 606 (558) PENCE - 'NEUTRAL'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.